Sweden's Devyser Diagnostics Q2 sales fall on distributor inventory adjustment
Sweden's Devyser Diagnostics Q2 sales fall on distributor inventory adjustment
Overview
Sweden diagnostics kit maker's Q2 net sales fell 10.7% yr/yr due to distributor inventory adjustment
Adjusted EPS for Q2 was SEK 0.10, with operating profit declining sharply
Company completed CyberGene AB acquisition on April 1, expanding in aneuploidy segment
Outlook
Company expects sales to largest distributor to remain lower for rest of 2026
Devyser expects sales to return to normal from 2027
Company maintains positive long-term outlook, citing strong demand and unchanged growth drivers
Result Drivers
DISTRIBUTOR INVENTORY - Co said Q2 sales were negatively impacted by a temporary inventory adjustment by its largest distributor
ITALY CONTRACT - Co won a SEK 8.9 mln contract in Italy
Company press release: ID:nMFN9Lz253
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Adjusted EPS |
| SEK 0.10 |
|
Q2 Net Income |
| SEK 1.60 mln |
|
Q2 EBIT |
| SEK 500,000 |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Devyser Diagnostics AB is SEK164.00, about 160.3% above its July 17 closing price of SEK63.00
The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 25 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)